%0 Journal Article
%A Santos-Garcia, Diego
%A de-Deus, Teresa
%A Cores, Carlos
%A Canfield, Hector
%A Paz-Gonzalez, Jose M
%A Martinez-Miro, Cristina
%A Valdes-Aymerich, Lorena
%A Suarez, Ester
%A Jesus, Silvia
%A Aguilar, Miquel
%A Pastor, Pau
%A Planellas, Lluis
%A Cosgaya, Marina
%A Garcia-Caldentey, Juan
%A Caballol, Nuria
%A Legarda, Ines
%A Hernandez-Vara, Jorge
%A Cabo, Iria
%A Lopez-Manzanares, Lydia
%A Gonzalez-Aramburu, Isabel
%A Avila-Rivera, Maria A
%A Catalan, Maria J
%A Nogueira, Victor
%A Puente, Victor
%A Dotor, Julio
%A Borrue, Carmen
%A Solano, Berta
%A Alvarez-Sauco, Maria
%A Vela, Lydia
%A Escalante, Sonia
%A Cubo, Esther
%A Carrillo, Francisco
%A Martinez-Castrillo, Juan C
%A Sanchez-Alonso, Pilar
%A Alonso, Gemma
%A Lopez-Ariztegui, Nuria
%A Gaston, Itziar
%A Kulisevsky, Jaime
%A Blazquez, Marta
%A Seijo, Manuel
%A Ruiz-Martinez, Javier
%A Valero, Caridad
%A Kurtis, Monica
%A de-Fabregues, Oriol
%A Ardura, Jessica
%A Alonso, Ruben
%A Ordas, Carlos
%A Lopez-Diaz, Luis M
%A McAfee, Darrian
%A Martinez-Martin, Pablo
%A Mir, Pablo
%T Predictors of Global Non-Motor Symptoms Burden Progression in Parkinson's Disease. Results from the COPPADIS Cohort at 2-Year Follow-Up.
%D 2021
%@ 2075-4426
%U http://hdl.handle.net/10668/18132
%X Background and Objective: Non-motor symptoms (NMS) progress in different ways between Parkinson’s disease (PD) patients . The aim of the present study was to (1) analyze the change in global NMS burden in a PD cohort after a 2-year follow-up, (2) to compare the changes with a control group , and (3) to identify predictors of global NMS burden progression in the PD group. Material and Methods : PD patients and controls, recruited from 35 centers of Spain from the COPPADIS cohort from January 2016 to November 2017, were followed-up with after 2 years. The Non-Motor Symptoms Scale (NMSS) was administered at baseline (V0) and at 24 months ± 1 month (V2). Linear regression models were used for determining predictive factors of global NMS burden progression (NMSS total score change from V0 to V2 as dependent variable). Results: After the 2-year follow-up, the mean NMS burden (NMSS total score) significantly increased in PD patients by 18.8% (from 45.08 ± 37.62 to 53.55 ± 42.28; p < 0.0001; N = 501; 60.2% males , mean age 62.59 ± 8.91) compared to no change observed in controls (from 14.74 ± 18.72 to 14.65 ± 21.82; p = 0.428; N = 122; 49.5% males , mean age 60.99 ± 8.32) (p < 0.0001). NMSS total score at baseline (β = −0.52), change from V0 to V2 in PDSS (Parkinson’s Disease Sleep Scale) (β = −0.34), and change from V0 to V2 in NPI (Neuropsychiatric Inventory ) (β = 0.25) provided the highest contributions to the model (adjusted R-squared 0.41; Durbin-Watson test = 1.865). Conclusions: Global NMS burden demonstrates short-term progression in PD patients but not in controls and identifies worsening sleep problems and neuropsychiatric symptoms as significant independent predictors of this NMS progression.
%K Parkinson’s disease
%K mood
%K non-motor symptoms
%K progression
%K quality of life
%~